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Abstract
Background: Familial adenomatous polyposis (FAP) is typically characterized by multiple colonic
polyps and frequent extracolonic features. Whereas the number of colonic polyps has been linked
to the APC gene mutation, possible genotype-phenotype correlations largely remain to be defined
for the extracolonic manifestations.
Methods:  Full genomic sequencing combined with multiplex ligation-dependent probe
amplification was used to identify APC gene mutations, which were correlated to the clinical
presentations.
Results:  10 novel APC  gene mutations were identified in 11 families. A broad spectrum of
extracolonic manifestations was identified in most of these individuals. Two sisters with an
insertion in codon 528 (c.1582_1583insGC) both showed severe phenotypes with classical
polyposis, upper gastrointestinal polyps and thyroid cancer. A woman with a 3'APC mutation
(c.5030_5031insAA) developed colon cancer at age 72 as the first manifestation of attenuated FAP.
Conclusion: With an increasing number of FAP families diagnosed, a broad and variable tumor
spectrum and a high frequency of extracolonic manifestations are gradually recognized. We report
novel APC mutations and present two FAP cases that suggest familial aggregation of thyroid cancer
and demonstrate the need to consider attenuated FAP also among elderly patients with colon
cancer.
Background
Familial adenomatous polyposis (FAP) affects about 1/
13–18000 individuals, is characterized by development of
multiple colonic polyps and causes less than 1% of color-
ectal cancer [1,2]. APC encodes for a 2843 amino acid pro-
tein that contains a variety of functional domains
involved in transcription, cell cycle control, migration,
differentiation, and apoptosis. Mutations in APC  were
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demonstrated in 1991 and to date some 800 mutations
have been identified [3,4]. Frameshift mutations predom-
inate and nonsense mutations are found in one third of
the cases, whereas large deletions and missense mutations
represent rare causes of FAP [5]. A mutation cluster region
in the 5'end of exon 15 of the APC gene has been identi-
fied and the two most frequent mutations, which account
for 11–17% of the germline alterations, affect codons
1061 and 1309 [5].
The severity of colonic polyposis has been linked to the
genotype. Mutations between APC codons 1250 and 1464
cause profuse polyposis, generally with > 5000 polyps,
and the recurrent codon 1309 mutation is associated with
early onset and development of thousands of polyps
[6,7]. The classical or intermediate phenotype is associ-
ated with mutations between codons 157 (in exon 4) and
1595 (in exon 15), whereas mutations before codon 157,
in the alternatively spliced region of exon 9, and after
codon 1595 cause attenuated FAP (AFAP) [8,9].
Extracolonic manifestations are estimated to develop in
70% of FAP patients [6]. Except for an association
between mutations in codons 311–1444 and congenital
hypertrophy of the retinal pigment epithelium (CHRPE),
extracolonic manifestations have been described in con-
junction with mutations throughout the APC  gene
[6,7,10]. We present new APC mutations and specifically
discuss two cases that demonstrate the broad phenotypic
spectrum in FAP; two sisters who concordantly developed
classical polyposis, upper gastrointestinal polyps, and thy-
roid cancer and a woman with a 3'APC mutation who pre-
sented with the first symptom of FAP at age 72.
Methods
All patients underwent genetic counseling and APC muta-
tion testing because of clinical suspicion of FAP. The study
complied with Ethics guidelines and the samples were
obtained as part of a clinical routine analysis with
informed consent. Totally, 15 individuals with clinical
FAP manifestations were subjected to mutation analysis,
which applied DNA sequencing of exons 1–14 and the
protein truncation test (PTT) to screen for truncating
mutations in exon 15 [for details see [11]]. Analysis for
large deletions was performed using the multiplex liga-
tion-dependent probe amplification (MLPA) assay in
cases where sequencing did not identify any mutation [for
details see [12]].
Results
Totally, 15 individuals with clinical FAP were subjected to
mutation analysis and APC gene mutations were identi-
fied in 11 individuals/families, whereas no mutation
could be identified in 4 individuals. Clinical characteris-
tics of the cases in which APC gene mutations were iden-
tified are summarized in table 1. The mutations included
4 small insertions/deletions, 3 nonsense mutations, 2
splice site mutations, and 2 whole-gene deletions
(detected by MLPA in cases A37 and A40). 5 individuals
reported no family history of polyposis/colorectal cancer.
Among patients with FAP-predisposing APC gene muta-
tions, colonic adenomas were diagnosed at surveillance or
because of symptoms at mean 32 (14–72) years of age.
Two individuals were diagnosed with colonic polyposis
and synchronous colon cancer at ages 45 and 72, respec-
tively. Duodenal polyps were diagnosed in 9 individuals
at mean 40 (24–73) years of age and gastric polyps devel-
oped in 7 individuals at mean 40 (26–73) years of age.
Desmoid tumors of the abdominal wall and the retroper-
itoneum developed in two patients at ages 20 and 73 and
were associated with mutations in exon 15.
Phenotypic similarity was demonstrated in two sisters
(A46-1 and A46-2) with an insertion
(c.1582_1583insGC) in an area of the APC gene associ-
ated with intermediate polyposis. They had a family his-
tory of FAP with a mother diagnosed with colonic and
duodenal polyposis who later developed a duodenal car-
cinoma from which she died. Both sisters developed
colon polyposis with the first adenomas diagnosed at ages
13 and 18. At ages 18 and 28, respectively, they were diag-
nosed with papillary thyroid cancer and underwent radi-
cal surgery. Upper gastrointestinal manifestations later
developed with duodenal polyps diagnosed at ages 27
and 28 and gastric polyps at ages 27 and 40.
Attenuated FAP was demonstrated in a woman without
family history of colorectal polyps or cancer. She devel-
oped synchronous colon cancers at age 72. One year later,
at age 73, she was diagnosed with duodenal and gastric
polyps and a desmoid tumor of the abdominal wall. The
synchronous colon cancers did not lead to clinical suspi-
cion of FAP, but the development of extracolonic features
linked to FAP prompted APC mutation analysis, which
identified an insertion (c.5030_5031insAA) in the 3'end
of the gene.
Discussion
Of the 10 previously unpublished mutations here
reported, 9 were located in the part of the APC gene asso-
ciated with classical FAP (table 1) [5,15]. New mutations
are estimated to cause 20–25% of FAP and 5 cases here
identified, including two individuals with whole-gene
APC  deletions, most likely represent new mutations
[14,15]. The expression of colonic polyposis, i.e. profuse,
classical and attenuated forms with variable ages at onset,
has in several studies been linked to the genotype,
whereas genotype-phenotype correlations for the extraco-
lonic features remain to define. Upper gastrointestinal
tumors include duodenal adenomas, which develop inBMC Medical Genetics 2008, 9:101 http://www.biomedcentral.com/1471-2350/9/101
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50–90% of individuals, fundic gland polyps in 40–50%,
and adenomas in the gastric antrum found in 5–20%. In
our series, all but one of the patients developed extraco-
lonic features and an increased risk has been described for
patients with mutations in exon 4, in codons 564–1465,
and in the 3'end of APC  [6,7,10]. Desmoid tumors
develop in 10–15% of FAP patients and have been associ-
ated with mutations distal to codon 1444, a family history
of desmoids and previous surgical trauma [16]. The two
cases with desmoids here identified support this link with
mutations located in codons 1450 and 1784. Several
other factors, e.g. prior abdominal surgery and modifying
genes, may however influence the risk. Identification of
such risk-predisposing factors would be clinically valua-
ble in order to determine the risk of desmoids tumor
development after prophylactic surgery.
Extraintestinal malignancies, i.e. thyroid cancer, hepatob-
lastoma, and brain tumors, develop only in a few percent
of FAP patients. Female FAP patients are at about 100
times increased risk of thyroid cancer, which typically
develop at age 30 [17,18]. Two sisters in our series devel-
oped papillary thyroid cancer at ages 19 and 28, respec-
tively. Although rare, thyroid cancer in first-degree
relatives has been reported in a small number of families
[19-21]. A link between thyroid cancer and mutations in
the 5'part of exon 15 (codons 1286 and 1513) has been
suggested [18]. Unfortunately, mutation data lack in most
of the other familial cases reported, but two families with
Table 1: Summary of genotypes and phenotypes
Family 
number
APC gene 
mutation
Consequence Type colonic 
polyposis 
(A, P, C)
Colonic 
adenoma age
Duodenal 
adenoma age
Gastric 
adenoma age
Other tumor 
type and 
location, Age
Family origin
A43/M c.824delA p.N276fs C 32 - - adenoma, 
ureter/32
Sweden
A8/F c.1120G>T p.S373X C 14 31 32 - Sweden
A19/M c.1409-1G>A intron 10 
splice site
C2 8 3 1 3 2 - S w e d e n
A46-1/F c.1582_1583i
nsGC
p.A529fs C 13 27 27 papillary 
cancer, thyroid/
19
Sweden
A46-2/F c.1582_1583i
nsGC
p.A529fs C 18 38 40 papillary 
cancer, thyroid/
28
Sweden
A29/M c.1690C>T p.R564X C 42 - - - Sweden
A34/F c.1958G>T exon 15 
splice site
P 44 44 - colon cancer/
45
Gambia
A26/F c.3921_3925d
elAAAAC
p.I1307fs C 22 40 47 - Sweden
A37/M del exon 1–15 c.1-
?_8532+?del
C2 2 2 4 2 6 - S w e d e n
A40/M del exon 1–15 c.1-
?_8532+?del
C 42 48 - adenomyoma, 
gall bladder/44
Macedonia
A47/M c.4348C>T p.R1450X C 20 - - desmoid 
tumor, 
retroperitoneu
m/20
Iceland
A30/F c.5030_5031i
nsAA
p.G1784fs A 72 73 73 osteoma/NA 
three 
synchronous 
colon cancers/
72
Sweden
desmoid 
tumor, 
abdominal wall/
73
osteoma/73 
adenocarcinom
a, small 
intestine/74
A: attenuated FAP, P: profuse FAP, C: classical FAP
NA: not availableBMC Medical Genetics 2008, 9:101 http://www.biomedcentral.com/1471-2350/9/101
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affected first-degree relatives and mutations 5' to codon
1513 have been reported. Our finding of thyroid cancer in
two sisters with the insertion c.1582_1583insGC pushes
the thyroid cancer associated region of APC further 3', but
until the genetic factors that cause thyroid cancer in FAP
have been delineated, caution is warranted for at-risk
females in families where thyroid cancer has been diag-
nosed.
AFAP with development of less than 100 colonic polyps
and a higher age at onset is estimated to represent 10% of
the cases [22]. The first symptom, i.e. development of
colon cancer at age 72 in an individual with a mutation in
codon 1784, i.e. within the 3' part of exon 15, reflects the
high risk of colon cancer despite a low number of polyps
in AFAP [9,23,24]. This woman also developed a desmoid
tumor and an osteoma at age 73 and an adenocarcinoma
of the small intestine at age 74. Mutations beyond codon
1600 are rare, but may be underestimated with currently
used mutation detection techniques. This case thus serves
as a reminder of the need to consider FAP in patients who
develop synchronous colorectal cancers and extracolonic
features also at older age.
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